Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT05300282
Title Study of Atezolizumab Plus BEGEV Regimen in Relapsed or Refractory Hodgkin's Lymphoma Patients (FIL_A-BEGEV)
Recruitment Not yet recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Fondazione Italiana Linfomi ONLUS

Hodgkin's lymphoma


Atezolizumab + Bendamustine + Gemcitabine + Vinorelbine

Bendamustine + Gemcitabine + Vinorelbine

Age Groups: adult
Covered Countries ITA

No variant requirements are available.